Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Clinuvel Pharmaceuticals ( (AU:CUV) ) has issued an update.
CLINUVEL Pharmaceuticals announced a significant milestone with the planned mid-2026 European regulatory filing for NEURACTHEL® Instant, a generic adrenocorticotropic hormone (ACTH) formulation. This follows the successful validation of the manufacturing process, ensuring a reliable supply chain and de-risking the commercial pathway. The strategic filing aims to accelerate market entry in key European markets with known demand, enhancing CLINUVEL’s portfolio of melanocortin-based therapies. The company is also investing in infrastructure to support future pharmaceutical products, aiming to broaden the clinical applications of ACTH and other melanocortins.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
CLINUVEL Pharmaceuticals is a global specialty pharmaceutical group focused on developing and commercializing treatments for genetic, metabolic, systemic, and life-threatening acute disorders, as well as healthcare solutions for specialized populations. Known for pioneering in photomedicine and melanocortin peptides, CLINUVEL has developed innovative treatments such as SCENESSE® for systemic photoprotection. Headquartered in Melbourne, Australia, the company operates in Europe, Singapore, and the USA.
Average Trading Volume: 127,923
Technical Sentiment Signal: Sell
Current Market Cap: A$597.4M
Find detailed analytics on CUV stock on TipRanks’ Stock Analysis page.